Clinical and genetic characteristics of rare variants of acromelic skeletal dysplasias caused by mutations in the FBN1 gene

Abstract

BACKGROUND: Geleophysic dysplasia and acromicric dysplasia are rare hereditary diseases characterized by dwarfism and dysplastic skeletal features. In the literature, only a few cases of geleophysic dysplasia and acromicric dysplasia caused by mutations in the FBN1 gene are described.

CLINICAL CASES: A description of the clinical and genetic characteristics of three female patients with acromelic dysplasias caused by three types of missense mutations in the FBN1 gene is presented. In two patients, on the basis of clinical manifestations and radiographic examination, acromicric dysplasia, and in one patient — geleophysic dysplasia were diagnosed. It was shown that all identified mutations were localized in exons of the FBN1 gene encoding the amino acid sequence of the fifth domain, which has homology with transforming growth factor-beta.

DISCUSSION: We have analyzed the clinical and genetic correlations to confirm the previously stated hypothesis about the occurrence of a severe phenotype of geleophysic dysplasia in patients with the c.5206T> C mutation. This mutation is characterized by the replacement of cysteine by arginine in the position of the polypeptide chain leading to moderate clinical manifestations of acromicric dysplasia in patients with the c.5284 G> A (p. Gly1762Ser). It was shown that the previously undescribed substitution c.5177G> A (p.Gly1726Asp and another previously described mutation in this codon resulted in the replacement of glutamine with valine. This mutation causes the appearance of a less pronounced phenotype of AD.

CONCLUSIONS: Based on the results of the examination of three Russian patients and analysis of clinical and radiographic parameters described in the literature, we reported that mutations in the FBN1 gene disrupted the amino acid sequence of the fifth like transforming growth factor-beta domain of fibrillin type 1. Importantly, these mutations are responsible for the occurrence of geleophysic dysplasia and acromicric dysplasia. However, the most severe clinical manifestations were observed in patients with mutations leading to the substitution of cysteine for arginine at the position of the polypeptide chain 1736. This may lead to affecting the transforming growth factor-beta signaling pathway.

Keywords

geleophysical dysplasia / acromicric dysplasia / fibrillin type 1

References

[1] Le Goff C, Mahaut C, Wang LW, et al. Mutations in the TGFbeta binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am J Hum Genet. 2011;89:7–14. DOI: 10.1016/j.ajhg.2011.05.012

[2] Le Goff C., Mahaut C., Wang L.W., et al. Mutations in the TGFbeta binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias // Am. J. Hum. Genet. 2011. Vol. 89. P. 7–14. DOI: 10.1016/j.ajhg.2011.05.012

[3] Spranger JW, Brill P, Hall C, et al. Bone dysplasias: an atlas of genetic disorders of skeletal development. 4th ed. USA: Oxford University Press; 2018. DOI: 10.1093/med/9780190626655.001.0001

[4] Spranger J.W., Brill P., Hall C., et al. Bone dysplasias: an atlas of genetic disorders of skeletal development. 4th ed. USA: Oxford University Press, 2018. DOI: 10.1093/med/9780190626655.001.0001

[5] Spranger JW, Gilbert EF, Tuffli GA, et al. Geleophysic dwarfismea “focal” mucopolysaccharidosis? Lancet. 1971;2:97–98. DOI: 10.1016/s0140-6736(71)92073-3

[6] Spranger J.W., Gilbert E.F., Tuffli G.A., et al. Geleophysic dwarfismea “focal” mucopolysaccharidosis? // Lancet. 1971. Vol. 2. P. 97–98. DOI: 10.1016/s0140-6736(71)92073-3

[7] Maroteaux P, Stanescu R, Stanescu V, et al. Acromicric dysplasia. Am J Med Genet. 1986;24:447–459. DOI: 10.1002/ajmg.1320240307

[8] Maroteaux P., Stanescu R., Stanescu V., et al. Acromicric dysplasia // Am. J. Med. Genet. 1986. Vol. 24. P. 447–459. DOI: 10.1002/ajmg.1320240307

[9] Scott A, Yeung S, Dickinson DF, et al. Natural history of cardiac involvement in geleophysic dysplasia. Am J Med Genet A. 2005;132A:320–323. DOI: 10.1002/ajmg.a.30450

[10] Scott A., Yeung S., Dickinson D.F., et al. Natural history of cardiac involvement in geleophysic dysplasia // Am. J. Med. Genet. A. 2005. Vol. 132A. P. 320–323. DOI: 10.1002/ajmg.a.30450

[11] Faivre L, Le Merrer M, Baumann C, et al. Acromicric dysplasia: long term outcome and evidence of autosomal dominant inheritance. J Med Genet. 2001;38:745–749. DOI: 10.1136/jmg.38.11.745

[12] Faivre L., Le Merrer M., Baumann C., et al. Acromicric dysplasia: long term outcome and evidence of autosomal dominant inheritance // J. Med. Genet. 2001. Vol. 38. P. 745–749. DOI: 10.1136/jmg.38.11.745

[13] Marzin P, Cormier-Daire V. Geleophysic dysplasia. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle: University of Washington; 1993. [cited 4 December 2018]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11168/

[14] Marzin P., Cormier-Daire V. Geleophysic dysplasia. In: Adam M.P., Ardinger H.H., Pagon R.A., et al., editors. GeneReviews®. Seattle: University of Washington, 1993. [дата обращения 4.12.2018]. Доступ по ссылке: http://www.ncbi.nlm.nih.gov/books/NBK11168/

[15] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. DOI: 10.1038/gim.2015.30

[16] Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology // Genet. Med. 2015. Vol. 17. No. 5. P. 405–424. DOI: 10.1038/gim.2015.30

[17] Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393–2419. DOI: 10.1002/ajmg.a.61366

[18] Mortier G.R., Cohn D.H., Cormier-Daire V., et al. Nosology and classification of genetic skeletal disorders: 2019 revision // Am. J. Med. Genet. A. 2019. Vol. 179. No. 12. P. 2393–2419. DOI: 10.1002/ajmg.a.61366

[19] Lipson AH, Kan AE, Kozlowski K, et al. Geleophysic dysplasia–acromicric dysplasia with evidence of glycoprotein storage. Am J Med Genet Suppl. 1987;3:181–189. DOI: 10.1002/ajmg.1320280522

[20] Lipson A.H., Kan A.E., Kozlowski K., et al. Geleophysic dysplasia–acromicric dysplasia with evidence of glycoprotein storage // Am. J. Med. Genet. Suppl. 1987. Vol. 3. P. 181–189. DOI: 10.1002/ajmg.1320280522

[21] Wraith JE, Bankier A, Chow CW, et al. Geleophysic dysplasia. Am J Med Genet. 1990;35(2):153–156. DOI: 10.1002/ajmg.1320350202

[22] Wraith J.E., Bankier A., Chow C.W., et al. Geleophysic dysplasia // Am. J. Med. Genet. 1990. Vol. 35. No. 2. P. 153–156. DOI: 10.1002/ajmg.1320350202

[23] Shohat M, Gruber HE, Pagon RA, et al. Geleophysic dysplasia: a storage disorder affecting the skin, bone, liver, heart, and trachea. J Pediatr. 1990;117(2 Pt 1):227–232. DOI: 10.1016/s0022-3476(05)80534-7

[24] Shohat M., Gruber H.E., Pagon R.A., et al. Geleophysic dysplasia: a storage disorder affecting the skin, bone, liver, heart, and trachea // J. Pediatr. 1990. Vol. 117. No. 2. Pt. 1. P. 227–232. DOI: 10.1016/s0022-3476(05)80534-7

[25] Marzin P, Thierry B, Dancasius A, et al. Geleophysic and acromicric dysplasias: natural history, genotype–phenotype correlations, and management guidelines from 38 cases. Genet Med. 2021;23(2):331–340. DOI: 10.1038/s41436-020-00994-x

[26] Marzin P., Thierry B., Dancasius A., et al. Geleophysic and acromicric dysplasias: natural history, genotype–phenotype correlations, and management guidelines from 38 cases // Genet. Med. 2021. Vol. 23. No. 2. P. 331–340. DOI: 10.1038/s41436-020-00994-x

[27] Klein C, Le Goff C, Topouchian V, et al. Orthopedics management of acromicric dysplasia: follow up of nine patients. Am J Med Genet. 2014;164A(2):331–337. DOI: 10.1002/ajmg.a.36139

[28] Klein C., Le Goff C., Topouchian V., et al. Orthopedics management of acromicric dysplasia: follow up of nine patients // Am. J. Med. Genet. 2014. Vol. 164A. No. 2. P. 331–337. DOI: 10.1002/ajmg.a.36139

[29] Stenson PD, Ball EV, Mort M, et al. Human gene mutation database (HGMD). Hum Mutat. 2003;21(6):577–581. DOI: 10.1002/humu.10212

[30] Stenson P.D., Ball E.V., Mort M., et al. Human gene mutation database (HGMD) // Hum. Mutat. 2003. Vol. 21. No. 6. P. 577–581. DOI: 10.1002/humu.10212

[31] Godwin ARF, Singh M, Lockhart-Cairns MP, et al. The role of fibrillin and microfibril binding proteins in elastin and elastic fibre assembly. Matrix Biol. 2019;84:17–30. DOI: 10.1016/j.matbio.2019.06.006

[32] Godwin A.R.F., Singh M., Lockhart-Cairns M.P., et al. The role of fibrillin and microfibril binding proteins in elastin and elastic fibre assembly // Matrix. Biol. 2019. Vol. 84. P. 17–30. DOI: 10.1016/j.matbio.2019.06.006

[33] Sun C, Xu D, Pei Z, et al. Separation in genetic pathogenesis of mutations in FBN1-TB5 region between autosomal dominant acromelic dysplasia and Marfan syndrome. Birth Defects Res. 2020;112(20):1834–1842. DOI: 10.1002/bdr2.1814

[34] Sun C., Xu D., Pei Z., et al. Separation in genetic pathogenesis of mutations in FBN1-TB5 region between autosomal dominant acromelic dysplasia and Marfan syndrome // Birth Defects Res. 2020. Vol. 112. No. 20. P. 1834–1842. DOI: 10.1002/bdr2.1814

[35] Jensen SA, Iqbal S, Bulsiewicz A, et al. A microfibril assembly assay identifies different mechanisms of dominance underlying Marfan syndrome, stiff skin syndrome and acromelic dysplasias. Hum Mol Genet. 2015;24(15):4454–4463. DOI: 10.1093/hmg/ddv181

[36] Jensen S.A., Iqbal S., Bulsiewicz A., et al. A microfibril assembly assay identifies different mechanisms of dominance underlying Marfan syndrome, stiff skin syndrome and acromelic dysplasias // Hum. Mol. Genet. 2015. Vol. 24. No. 15. P. 4454–4463. DOI: 10.1093/hmg/ddv181

[37] Hasegawa K, Numakura C, Tanaka H, et al. Three cases of Japanese acromicric/geleophysic dysplasia with FBN1 mutations: a comparison of clinical and radiological features. J Pediatr Endocrinol Metab. 2017;30(1):117–121. DOI: 10.1515/jpem-2016-0258

[38] Hasegawa K., Numakura C., Tanaka H., et al. Three cases of Japanese acromicric/geleophysic dysplasia with FBN1 mutations: a comparison of clinical and radiological features // J. Pediatr. Endocrinol. Metab. 2017. Vol. 30. No. 1. P. 117–121. DOI: 10.1515/jpem-2016-0258

[39] Cheng SW, Luk HM, Chu YWY, et al. A report of three families with FBN1-related acromelic dysplasias and review of literature for genotype-phenotype correlation in geleophysic dysplasia. Eur J Med Genet. 2018;61(4):219–224. DOI: 10.1016/j.ejmg.2017.11.018

[40] Cheng S.W., Luk H.M., Chu Y.W.Y., et al. A report of three families with FBN1-related acromelic dysplasias and review of literature for genotype-phenotype correlation in geleophysic dysplasia // Eur. J. Med. Genet. 2018. Vol. 61. No. 4. P. 219–224. DOI: 10.1016/j.ejmg.2017.11.018

[41] Maddirevula S, Alsahli S, Alhabeeb L, et al. Expanding the phenome and variome of skeletal dysplasia. Genet Med. 2018;20(12):1609–1616. DOI: 10.1038/gim.2018.50

[42] Maddirevula S., Alsahli S., Alhabeeb L., et al. Expanding the phenome and variome of skeletal dysplasia // Genet. Med. 2018. Vol. 20. No. 12. P. 1609–1616. DOI: 10.1038/gim.2018.50

[43] Moey LH, Flaherty M, Zankl A. Optic disc swelling in acromicric and geleophysic dysplasia. Am J Med Genet A. 2019;179(9): 1898–1901. DOI: 10.1002/ajmg.a.61268

[44] Moey L.H., Flaherty M., Zankl A. Optic disc swelling in acromicric and geleophysic dysplasia // Am. J. Med. Genet. A. 2019. Vol. 179. No. 9. P. 1898–1901. DOI: 10.1002/ajmg.a.61268

RIGHTS & PERMISSIONS

Markova T.V., Kenis V.M., Melchenko E.V., Nagornova T.S., Murtazina A.F., Dadali E.L.